GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (MIL:1EVT) » Definitions » Gross Margin %

Evotec SE (MIL:1EVT) Gross Margin % : 9.89% (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Evotec SE Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Evotec SE's Gross Profit for the three months ended in Sep. 2024 was €18.3 Mil. Evotec SE's Revenue for the three months ended in Sep. 2024 was €184.9 Mil. Therefore, Evotec SE's Gross Margin % for the quarter that ended in Sep. 2024 was 9.89%.

Warning Sign:

Evotec SE gross margin has been in long-term decline. The average rate of decline per year is -6.1%.


The historical rank and industry rank for Evotec SE's Gross Margin % or its related term are showing as below:

MIL:1EVT' s Gross Margin % Range Over the Past 10 Years
Min: 13.7   Med: 28.64   Max: 35.59
Current: 13.7


During the past 13 years, the highest Gross Margin % of Evotec SE was 35.59%. The lowest was 13.70%. And the median was 28.64%.

MIL:1EVT's Gross Margin % is ranked worse than
92.47% of 970 companies
in the Drug Manufacturers industry
Industry Median: 46.94 vs MIL:1EVT: 13.70

Evotec SE had a gross margin of 9.89% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Evotec SE was -6.10% per year.


Evotec SE Gross Margin % Historical Data

The historical data trend for Evotec SE's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Gross Margin % Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.77 25.10 24.52 23.16 22.40

Evotec SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.27 18.71 16.65 8.64 9.89

Competitive Comparison of Evotec SE's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Evotec SE's Gross Margin % falls into.



Evotec SE Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Evotec SE's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=175.1 / 781.426
=(Revenue - Cost of Goods Sold) / Revenue
=(781.426 - 606.375) / 781.426
=22.40 %

Evotec SE's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=18.3 / 184.89
=(Revenue - Cost of Goods Sold) / Revenue
=(184.89 - 166.607) / 184.89
=9.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Evotec SE  (MIL:1EVT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Evotec SE had a gross margin of 9.89% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Evotec SE Gross Margin % Related Terms

Thank you for viewing the detailed overview of Evotec SE's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE Headlines

No Headlines